TLX
Telix Pharmaceuticals Ltd
Biotechnology
·
Healthcare
55
comments
22
fund managers
past 90 days
About Telix Pharmaceuticals Ltd
Telix Pharmaceuticals Limited is a Melbourne-based biopharmaceutical company focused on the development and commercialization of clinical-stage radiopharmaceutical oncology assets. Founded in 2015, the company operates across three segments: Commercial, Product Development, and Group and Unallocated. Its primary commercial asset is Illuccix. The pipeline targets prostate, renal, and glioblastoma cancers, with key products including TLX250, TLX591, and TLX101. Telix specializes in advanced cancer care solutions, driving innovation in molecularly-targeted radiation through its global product development and regulatory efforts.
Commentary Volume
55
Comments
22
Fund managers
0
Past 90 days
SOURCE
ACTION
COMMENT PREVIEW
FUND MANAGER
DATE
Loading...
.
​Loading...
Loading...
Loading...
Loading...
Source: Ipsum Capital Q4 Quarterly Letter · Published 14 March 2025
Report a problem
Loading...
.
Loading...
Loading...
Loading...
Loading...
§ Important Notice
The entries below are records originating from third-party statements. Thesis Tracker does not rank, recommend or endorse any fund manager, fund or security. Investment decisions should be made on the basis of the relevant Product Disclosure Statement and, where appropriate, advice from a licensed adviser.
Commentary
Sector
Healthcare
Market cap
$5B
Fund managers
22 managers
First covered
30 June 2023
Last updated
30 Apr 2026
Company Details
Related Themes
ic
Ipsum Capital
6 comments
ic
Amet Funds
4 comments
ic
Dolor
3 comments
Top Investors Covering MIN
§ Reminder
The entries above are records originating from third-party statements. Thesis Tracker does not rank, recommend or endorse any fund manager, fund or security. Investment decisions should be made on the basis of the relevant Product Disclosure Statement and, where appropriate, advice from a licensed adviser.
Frequently asked questions about Telix Pharmaceuticals Ltd (ASX:TLX)
Frequently asked questions
Who is investing in Telix Pharmaceuticals Ltd (ASX:TLX)?
Fund managers including Milford Asset Management, Monash Investors, Equity Trustees Asset Management, Yarra Capital Management, Pengana Capital Group, Mint Asset Management, Selector Funds Management, Clime Investment Management, Glennon Small Companies, Bennelong Australian Equity Partners, Sage Capital, SG Hiscock & Company, Antares Capital, Perennial Partners, Sterling Managed Investments, Eiger Capital, Australian Eagle Asset Management, Perennial Value Management, Pendal Group, Greencape Capital, Ellerston Capital and Lennox Capital Partners have invested in Telix Pharmaceuticals Ltd (ASX:TLX).
What is the short interest in Telix Pharmaceuticals Ltd (ASX:TLX)?
The short interest in Telix Pharmaceuticals Ltd (ASX:TLX) is 10.89% which makes it the eighth most shorted stock on the ASX. Of the 338.7M shares that Telix Pharmaceuticals Ltd has on issue, 36.9M have been sold short.
What does Telix Pharmaceuticals Ltd (ASX:TLX) do?
Telix Pharmaceuticals Limited is a Melbourne-based biopharmaceutical company focused on the development and commercialization of clinical-stage radiopharmaceutical oncology assets. Founded in 2015, the company operates across three segments: Commercial, Product Development, and Group and Unallocated. Its primary commercial asset is Illuccix. The pipeline targets prostate, renal, and glioblastoma cancers, with key products including TLX250, TLX591, and TLX101. Telix specializes in advanced cancer care solutions, driving innovation in molecularly-targeted radiation through its global product development and regulatory efforts.
Loading...